AN2 Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
AN2 Therapeutics Inc
TickerANTX
CIK #0001880438
CUSIP036752202
SectorLife Sciences - Pharmaceutical Preparations
Address1800 El Camino Real, Suite D, Menlo Park, CA 94027
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
AN2 Therapeutics Inc 2026-03-25 40.0 M Exemption: 506(b) · Duration: One year or less · Commission: $2,400,003 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001880438] 10-K
[0001880438] 10-Q
[0001880438] 3
[0001880438] 4
[0001880438] 8-K
[0001880438] D
[0001880438] SC 13D
[0001880438] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Commodore Capital LP AN2 Therapeutics Inc [2026-03-16] 0.0
Integrated Core Strategies US LLC AN2 Therapeutics Inc [2026-03-13] 0.0
Vivo Opportunity Fund Holdings LP AN2 Therapeutics Inc [2026-03-13] 0.0
Almitas Capital LLC AN2 Therapeutics Inc [2026-02-17] 0.0
Almitas Capital LLC AN2 Therapeutics Inc [2025-11-14] 0.0
Coastlands Capital Partners LP AN2 Therapeutics Inc [2025-06-04] 0.0
BML Investment Partners LP AN2 Therapeutics Inc [2025-05-07] 0.0
BML Investment Partners LP AN2 Therapeutics Inc [2024-08-12] 14.2
Octagon Capital Advisors LP AN2 Therapeutics Inc [2024-07-03] 10.1
Frazier Life Sciences Public Fund LP AN2 Therapeutics Inc [2024-04-10] 81942.4
Easom Eric AN2 Therapeutics Inc [2024-02-13] 81945.2
TCG Crossover GP I LLC AN2 Therapeutics Inc [2023-07-25] 6.6
Janus Henderson Group PLC AN2 Therapeutics Inc [2023-07-05] 5.1
BRII Biosciences Ltd AN2 Therapeutics Inc [2023-02-13] 5.4
Pfizer Inc AN2 Therapeutics Inc [2023-02-13] 7.02
Adjuvant Global Health Technology Fund LP AN2 Therapeutics Inc [2023-02-10] 11.3
Citadel Advisors LLC AN2 Therapeutics Inc [2022-04-08] 7.1
RA Capital Management LP AN2 Therapeutics Inc [2022-04-08] 19.6
Biotechnology Value Fund L P AN2 Therapeutics Inc [2022-04-04] 4.7
Form 3/4/5 Filer 2011 - 2026
AN2 Therapeutics Inc
Williams Sarah Joanne
Aziz Kabeer
Marks Gilbert Lynn
Martin Patricia A
Spigelman Melvin K
Easom Eric
Readnour Robin Shane
Day Lucy
Chanda Sanjay
FitzPatrick Margaret M
Wong Stephanie
Zakrzewski Joseph S
Eizen Joshua M
Prior Stephen David
Leonard Braden Michael
Shah Rajeev M
RA Capital Healthcare Fund LP
RA Capital Nexus Fund II LP
RA Capital Management LP
Kolchinsky Peter
Krause Kevin Michael
Eckburg Paul
Adjuvant Capital Management LLC
Adjuvant Global Health Technology Fund LP
Adjuvant Capital GP LP
Adjuvant Global Health Technology Fund DE LP
Nazak Michael Adrian
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Eizen Joshua M
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 50,150
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 23,742
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 10,362
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Grant 10,362
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 16,941
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Grant 23,742
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Grant 249,999
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 267,650
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 249,999
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Grant 225,000
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 225,000
Easom Eric
Stock Option (right to buy) · derivative
2026-03-19 Grant 267,650
Readnour Robin Shane
Stock Option (right to buy) · derivative
2026-03-19 Grant 23,742
Readnour Robin Shane
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 20,724
Readnour Robin Shane
Stock Option (right to buy) · derivative
2026-03-19 Grant 20,724
Readnour Robin Shane
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 23,742
Spigelman Melvin K
Stock Option (right to buy) · derivative
2026-03-19 Grant 16,941
Day Lucy
Stock Option (right to buy) · derivative
2026-03-19 Grant 82,300
Day Lucy
Stock Option (right to buy) · derivative
2026-03-19 Disposed to issuer 66,000
Day Lucy
Stock Option (right to buy) · derivative
2026-03-19 Grant 66,000
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 53 21,894,481
2025-12-31 38 8,664,576
2025-09-30 36 9,704,641
2025-06-30 38 8,284,558
2025-03-31 39 14,340,831
2024-12-31 39 14,528,931
2024-09-30 33 13,513,279
2024-06-30 47 19,515,208
2024-03-31 56 18,741,893
2023-12-31 53 20,643,113
2023-09-30 39 19,931,491
2023-06-30 33 11,741,515
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com